Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PCRX 
Pacira BioSciences, Inc. (PCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PCRX (1-star) is a SELL. SELL since 4 days. Profits (-10.58%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.4
1 Year Target Price $30.4
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.05% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.11B USD | Price to earnings Ratio - | 1Y Target Price 30.4 |
Price to earnings Ratio - | 1Y Target Price 30.4 | ||
Volume (30-day avg) 6 | Beta 0.51 | 52 Weeks Range 11.16 - 28.63 | Updated Date 06/30/2025 |
52 Weeks Range 11.16 - 28.63 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -14.76% | Operating Margin (TTM) 4.63% |
Management Effectiveness
Return on Assets (TTM) 3.56% | Return on Equity (TTM) -12.27% |
Valuation
Trailing PE - | Forward PE 9.32 | Enterprise Value 1230066581 | Price to Sales(TTM) 1.57 |
Enterprise Value 1230066581 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA 43.89 | Shares Outstanding 46304700 | Shares Floating 45834212 |
Shares Outstanding 46304700 | Shares Floating 45834212 | ||
Percent Insiders 1.84 | Percent Institutions 111.09 |
Analyst Ratings
Rating 3 | Target Price 30.4 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pacira BioSciences, Inc.
Company Overview
History and Background
Pacira BioSciences, Inc. was founded in 2006. Initially focused on post-surgical pain management, the company has evolved through strategic acquisitions and product development, expanding its portfolio and market reach in non-opioid pain management solutions.
Core Business Areas
- Post-Surgical Pain Management: Pacira's core business focuses on providing non-opioid pain management solutions to reduce or eliminate the need for opioid-based pain medications after surgery.
- Nerve Block Solutions: The company develops and commercializes products designed to deliver localized pain relief through nerve blocks.
Leadership and Structure
Pacira BioSciences, Inc. is led by a seasoned executive team with expertise in pharmaceuticals and healthcare. The organizational structure includes departments for research and development, sales and marketing, manufacturing, and finance, with a focus on commercializing and expanding their product portfolio.
Top Products and Market Share
Key Offerings
- EXPAREL (bupivacaine liposome injectable suspension): EXPAREL is Pacira's flagship product, a long-acting local anesthetic used for single-dose infiltration in adults to produce postsurgical analgesia. EXPAREL has a significant market share in the non-opioid pain management segment. Competitors include local anesthetics and other pain management strategies, though EXPAREL's long-acting nature gives it a competitive advantage. Revenue from EXPAREL is the majority of the company's revenue.
- ioverau00b0: ioverau00b0 uses focused cold therapy to deliver immediate pain relief without the use of opioids. It competes with other pain relief methods and is used in procedures where targeted pain management is needed. Details on specific market share and revenue from ioverau00b0 is less readily available in public sources. Competitors include nerve ablation, steroid injections, and other pain management devices.
Market Dynamics
Industry Overview
The pain management market is growing due to an aging population, increasing surgical procedures, and a rising awareness of the risks associated with opioid-based pain medications. The demand for non-opioid alternatives is increasing due to the opioid crisis.
Positioning
Pacira BioSciences, Inc. is positioned as a leader in the non-opioid pain management market, particularly with its flagship product EXPAREL. Its competitive advantage lies in its proprietary liposomal technology, which provides extended pain relief.
Total Addressable Market (TAM)
The global pain management market is estimated to be in the tens of billions of dollars. Pacira BioSciences, Inc. is targeting a substantial portion of this TAM by offering innovative non-opioid solutions and expanding its product line.
Upturn SWOT Analysis
Strengths
- Proprietary liposomal technology
- Strong brand recognition for EXPAREL
- Focus on non-opioid pain management
- Established sales and marketing infrastructure
Weaknesses
- Reliance on a limited number of key products
- Potential for generic competition
- Manufacturing complexities
- High R&D Expenses
Opportunities
- Expanding into new geographic markets
- Developing new non-opioid pain management solutions
- Acquiring complementary technologies or products
- Increasing adoption of EXPAREL in various surgical procedures
Threats
- Increased competition from other pharmaceutical companies
- Regulatory changes impacting drug approval processes
- Pricing pressures from healthcare providers and payers
- Potential for product liability lawsuits
Competitors and Market Share
Key Competitors
- BHC
- CRL
- TEVA
Competitive Landscape
Pacira BioSciences, Inc. has a competitive advantage in the non-opioid pain management market due to its proprietary liposomal technology. However, it faces competition from other pharmaceutical companies that offer pain management solutions.
Major Acquisitions
Flexion Therapeutics
- Year: 2021
- Acquisition Price (USD millions): 450
- Strategic Rationale: Acquisition of Flexion Therapeutics added Zilretta, a non-opioid treatment for osteoarthritis knee pain, to Pacira's portfolio.
Growth Trajectory and Initiatives
Historical Growth: Pacira BioSciences, Inc. has experienced significant revenue growth in recent years, driven by increased adoption of EXPAREL and other products.
Future Projections: Future growth is expected to be driven by expanding the use of EXPAREL in new surgical procedures and geographic markets, as well as developing and commercializing new non-opioid pain management solutions.
Recent Initiatives: Recent initiatives include expanding the EXPAREL label, acquiring new technologies, and investing in R&D.
Summary
Pacira BioSciences is a leading company in the non-opioid pain management space, primarily driven by its flagship product, EXPAREL. The company's financial performance has been strong, but the reliance on EXPAREL and potential for generic competition are key risks. Growth opportunities exist through geographical expansion and new product development. While not currently paying dividends, Pacirau2019s shareholder returns depend on stock price appreciation. The company's fundamentals point to a strong position within a growing market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacira BioSciences, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2011-02-03 | CEO & Director Mr. Frank D. Lee | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 788 | Website https://www.pacira.com |
Full time employees 788 | Website https://www.pacira.com | ||
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. The company has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.